Skip to content

A randomized controlled study for Endostar combined with PF regimen concurrent radiotherapy compare with PF regimen concurrent radiotherapy for Advanced esophageal cancer

A randomized controlled study for Endostar combined with PF regimen concurrent radiotherapy compare with PF regimen concurrent radiotherapy for Advanced esophageal cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022095
Enrollment
Unknown
Registered
2019-03-24
Start date
2019-04-01
Completion date
Unknown
Last updated
2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

Sponsors

Red Cross Hosptical of Yulin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years, male or female; 2. Histopathologically confirmed esophageal squamous cell carcinoma and esophageal adenocarcinoma. 3. Clinical stage II to IVa; 4. Karl's score (> 70) 5. There are measurable lesions (RECIST version 1.1); 6. This treatment must be the first course of treatment; 7. Expected survival =6 months; 8. Laboratory inspections meet the following requirements: WBC = 4.0×10^9/L, neutrophil count = 2.0×10^9/L, PLT = 100×10^9/L; total bilirubin, ALT, AST = 1.25 times the upper limit of normal; PT is within the upper limit of normal value. 9. Participants voluntarily joined the study, signed informed consent; 10. Participants had good compliance and follow-up.

Exclusion criteria

Exclusion criteria: 1. Have a distant metastasis; 2. History of malignancy in other sites; 3. Chemotherapy and chest radiotherapy before the start of the trial; 4. Radiotherapy and chemotherapy contraindications include severe infections or other complications such as myocardial infarction, severe arrhythmia, severe cerebrovascular disease, psychosis and uncontrollable diabetes mellitus; 5. Received target therapies; 6. Haemorrhagic tendencies; 7. There is tracheoesophageal fistulas.

Design outcomes

Primary

MeasureTime frame
Objective response rate;disease control rate;progression-free survival;Overall survival;

Secondary

MeasureTime frame
drug safety;Liver and kidney function;

Countries

China

Contacts

Public ContactGao Yang
991gaoyang@163.com+86 13977588462

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026